Literature DB >> 27288799

Pathological Gambling in Parkinson's disease patients: Dopaminergic medication or personality traits fault?

L Brusa1, V Pavino2, M C Massimetti2, R Ceravolo3, S Stefani4, P Stanzione4.   

Abstract

Impulse control disorders (ICDs) are clinically relevant in Parkinson disease (PD) patients, with an established association with PD medication. Aim of our study was to study whether the increased frequency of pathological gambling (PG), reported in subgroups of PD patients, is related to specific personality tracts additional to dopaminergic medications. Thirty-seven PD patients with a personal history of PG where enrolled. Twenty one PD patients, matched for disease and dopaminergic therapy, never experiencing PG, were enrolled as controls. All subjects were tested with the Minnesota Multiphasic Inventory Personality scales (MMPI-2). Our data showed that PD group with PG exhibited significantly higher mean values of the three validity scales in comparison to the non-PG-PD group, demonstrating an higher tendency to lie. Content scales showed a significant increase of cynicism and bizarre ideation scales score in the PG-PD group, not exhibiting pathological values at the validity scales, (p: 0.02) in comparison to non-PG PD patients. According to our results, PG seems to be associated with precise personality tracts. Personality profiles of cluster A personality disturbances - Axys 2 according with DSM-5 TR (paranoid type) at MMPI-2 might be a warning index helpful in selecting dopaminergic treatment, to avoid subsequent ICDs appearance.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  MMPI; Parkinson's disease; Pathological gambling; Personality

Mesh:

Substances:

Year:  2016        PMID: 27288799     DOI: 10.1016/j.jns.2016.03.032

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  7 in total

1.  Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias.

Authors:  Silvia Picazio; Viviana Ponzo; Carlo Caltagirone; Livia Brusa; Giacomo Koch
Journal:  J Neurol       Date:  2018-07-06       Impact factor: 4.849

2.  Impulse control behaviors and subthalamic deep brain stimulation in Parkinson disease.

Authors:  Aristide Merola; Alberto Romagnolo; Laura Rizzi; Mario Giorgio Rizzone; Maurizio Zibetti; Michele Lanotte; George Mandybur; Andrew P Duker; Alberto J Espay; Leonardo Lopiano
Journal:  J Neurol       Date:  2016-10-19       Impact factor: 4.849

Review 3.  Medications, Deep Brain Stimulation, and Other Factors Influencing Impulse Control Disorders in Parkinson's Disease.

Authors:  Robert S Eisinger; Adolfo Ramirez-Zamora; Samuel Carbunaru; Brandon Ptak; Zhongxing Peng-Chen; Michael S Okun; Aysegul Gunduz
Journal:  Front Neurol       Date:  2019-02-26       Impact factor: 4.003

4.  Risk factors for impulse control disorders and related behaviors in Parkinson's disease: secondary analyses of the ICARUS study.

Authors:  Paolo Barone; Angelo Antonini; Paolo Stanzione; Karin Annoni; Mahnaz Asgharnejad; Ubaldo Bonuccelli
Journal:  J Drug Assess       Date:  2019-10-04

Review 5.  Human moral decision-making through the lens of Parkinson's disease.

Authors:  Giorgia Ponsi; Marina Scattolin; Riccardo Villa; Salvatore Maria Aglioti
Journal:  NPJ Parkinsons Dis       Date:  2021-03-02

Review 6.  Dopamine Agonists and Impulse Control Disorders: A Complex Association.

Authors:  Marie Grall-Bronnec; Caroline Victorri-Vigneau; Yann Donnio; Juliette Leboucher; Morgane Rousselet; Elsa Thiabaud; Nicolas Zreika; Pascal Derkinderen; Gaëlle Challet-Bouju
Journal:  Drug Saf       Date:  2018-01       Impact factor: 5.606

7.  A Comparison of Treatment-Seeking Behavioral Addiction Patients with and without Parkinson's Disease.

Authors:  Anne Sauvaget; Susana Jiménez-Murcia; Fernando Fernández-Aranda; Roser Granero; Marie Grall-Bronnec; Caroline Victorri-Vigneau; Samuel Bulteau; Pascal Derkinderen; Jean M Vanelle; Anders Hakansson; Gemma Mestre-Bach; Trevor Steward; José M Menchón
Journal:  Front Psychiatry       Date:  2017-11-03       Impact factor: 4.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.